HomeCompareJXJT vs JNJ

JXJT vs JNJ: Dividend Comparison 2026

JXJT yields 247.68% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JXJT wins by $434.53M in total portfolio value
10 years
JXJT
JXJT
● Live price
247.68%
Share price
$0.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$434.56M
Annual income
$242,199,531.02
Full JXJT calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — JXJT vs JNJ

📍 JXJT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJXJTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JXJT + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JXJT pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JXJT
Annual income on $10K today (after 15% tax)
$21,052.63/yr
After 10yr DRIP, annual income (after tax)
$205,869,601.37/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JXJT beats the other by $205,865,615.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JXJT + JNJ for your $10,000?

JXJT: 50%JNJ: 50%
100% JNJ50/50100% JXJT
Portfolio after 10yr
$217.30M
Annual income
$121,102,110.21/yr
Blended yield
55.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

JXJT
No analyst data
Altman Z
-1.7
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JXJT buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJXJTJNJ
Forward yield247.68%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$434.56M$30.3K
Annual income after 10y$242,199,531.02$4,689.40
Total dividends collected$413.96M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JXJT vs JNJ ($10,000, DRIP)

YearJXJT PortfolioJXJT Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$35,468$24,767.80$10,592$272.30+$24.9KJXJT
2$120,050$82,099.02$11,289$357.73+$108.8KJXJT
3$388,158$259,705.11$12,123$472.89+$376.0KJXJT
4$1,200,104$784,774.42$13,141$629.86+$1.19MJXJT
5$3,551,735$2,267,624.33$14,408$846.81+$3.54MJXJT
6$10,072,402$6,272,044.91$16,021$1,151.60+$10.06MJXJT
7$27,400,792$16,623,322.56$18,122$1,588.22+$27.38MJXJT
8$71,582,219$42,263,371.68$20,930$2,228.20+$71.56MJXJT
9$179,779,361$103,186,386.19$24,792$3,191.91+$179.75MJXJT
10$434,563,447$242,199,531.02$30,274$4,689.40+$434.53MJXJT

JXJT vs JNJ: Complete Analysis 2026

JXJTStock

JX Luxventure Limited, a casual menswear company, designs, develops, markets, and sells fashion menswear products in the People's Republic of China. The company operates through five segments: Wholesale, Retail, Contract Manufacturing, Tourism Service, and Cross-Border E-Commerce. It offers apparel products, including cotton and down jackets, sweaters, suits, shirts, T-shirts, jeans, and trousers; accessories, such as shoes, bags, belts, socks, and caps; and footwear for urban males between the ages of 20 and 40. As of December 31, 2021, the company owned and operated 1 corporate store and 29 franchised stores. It also provides packaged group tour services online through the Luxventure platform; and engages in the offline wholesale of health care, personal care, cosmetics, maternal and child, pet-related, and universal cuisine and household products, as well as online. In addition, the company offers tourism and selling carrier services. The company was formerly known as KBS Fashion Group Limited and changed its name to JX Luxventure Limited in October 2021. JX Luxventure Limited is headquartered in Haikou, the People's Republic of China.

Full JXJT Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this JXJT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JXJT vs SCHDJXJT vs JEPIJXJT vs OJXJT vs KOJXJT vs MAINJXJT vs ABBVJXJT vs MRKJXJT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.